HC Wainwright & Co. maintains uniQure at Buy, lowers price target to $65 from $80
HC Wainwright & Co. kept uniQure's rating at Buy but reduced its price target from $80 to $65, an 18.8% cut. The new target suggests a 212.8% upside from the Nov 17 close of $20.78, according to the firm.
How this was made

The 30-second read
Why it matters
Lowering the price target reduces the valuation benchmark used by some investors, which can weigh on sentiment even when the rating stays Buy.
Market read
This is a single-name valuation adjustment, likely affecting short-term sentiment more than fundamentals.
What to watch
The article provides no thesis details behind the target cut, so traders may need to check the underlying analyst rationale before assuming fundamental deterioration.
Background
The piece is an analyst-research update: HC Wainwright keeps uniQure at Buy while lowering its price target.
Ticker impact
HC Wainwright maintains uniQure at Buy but cuts its price target to $65 from $80, signaling a lower valuation despite the Buy rating.
Shares may face mild downside or underperformance as the market digests the lower target, unless other catalysts offset it.
The article discloses only an analyst price-target reduction (no new company fundamentals). That typically affects sentiment and positioning more than fundamentals, so impact is likely limited but directionally negative.
Market effects
Limited read-through to gene therapy peers since this is a single-name target cut without new sector data.
No clear regional spillover implied by the article.
Minimal global relevance; this is a US analyst target update for a single company.
Counterpoint
A maintained Buy rating can still support dip-buying, especially if the market focuses on the implied upside rather than the reduced target.
Key entities
- companyuniQure
Gene therapy company referenced as the subject of the analyst rating and price-target change.
- analyst_firmHC Wainwright & Co.
Brokerage issuing the maintained Buy rating and reduced price target.


